Interactive Roundtable Discussion – Audiences follow-on reflections from the panel
- How should we integrate multi-modal endpoints into IPF trial design without overcomplicating execution?
- What evidence is still needed for broader regulatory acceptance of imaging and novel endpoints?
- Are current endpoint strategies in IPF still fit for purpose in an era of combination therapies and smaller treatment effects?